SI
APLS

Symmetry Investments’s Apellis Pharmaceuticals APLS Stock Holding History

Symmetry Investments’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,500
Closed -$319K – 146
2023
Q2 		$319K Buy
+3,500
New +$302K 0.05% 141

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Symmetry Investments's APLS Position: Q3 2023 in Review

Symmetry Investments sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 3,500 shares — an estimated $319K sold.

Symmetry Investments first reported a position in APLS in Q2 2023 and held it in 1 quarter. The position peaked at $319K in Q2 2023. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

  • Symmetry Investments reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Symmetry Investments sold 3,500 Apellis Pharmaceuticals shares in Q3 2023, an estimated $319K.
  • Symmetry Investments first reported a position in Apellis Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Symmetry Investments's Apellis Pharmaceuticals position peaked at $319K in Q2 2023.
  • 256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on Symmetry Investments's 13F filing for Q3 2023, filed 14 Nov 2023.